Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Philadelphia Chromosome (BCR/ABL Quantitative) Test

The maximum days for obtaining the report for the Philadelphia Chromosome (BCR/ABL Quantitative) Test is 7 business days. This test is important for detecting certain types of leukemia and monitoring the response to treatment.

What are the prerequisites for the test Philadelphia Chromosome (BCR/ABL Quantitative) Test

  • Patient must have a suspected or confirmed diagnosis of chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL)
  • Patient must have a physician's order for the test
  • Patient must not have received recent blood transfusions
  • Patient must not have received recent chemotherapy or radiation therapy
  • Patient must not have a history of bone marrow transplant

What are the measure values for the test Philadelphia Chromosome (BCR/ABL Quantitative) Test

  • Positive: BCR/ABL fusion gene is detected in the sample
  • Negative: BCR/ABL fusion gene is not detected in the sample
  • Quantitative Results: Percentage of BCR/ABL fusion gene present in the sample

What does this test Philadelphia Chromosome (BCR/ABL Quantitative) Test identify?

The Philadelphia Chromosome (BCR/ABL Quantitative) Test identifies the presence of a specific genetic abnormality known as the Philadelphia chromosome, which is commonly found in patients with chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).

The test measures the levels of the BCR/ABL fusion gene, which is created by the translocation of genetic material between chromosomes 9 and 22. This fusion gene produces a protein that promotes the uncontrolled growth of cancer cells, leading to the development of leukemia.

By quantifying the amount of BCR/ABL gene present in a patient's blood or bone marrow sample, the test can help monitor the effectiveness of treatment and detect any signs of disease progression or relapse.

Why is this test Philadelphia Chromosome (BCR/ABL Quantitative) Test taken?

Philadelphia Chromosome (BCR/ABL Quantitative) Test

The Philadelphia Chromosome (BCR/ABL Quantitative) Test is taken to diagnose and monitor chronic myeloid leukemia (CML) and some types of acute lymphoblastic leukemia (ALL). It measures the amount of the BCR/ABL fusion gene, which is created by the Philadelphia chromosome, in the blood or bone marrow.

This test is important because the presence and level of the BCR/ABL fusion gene can help determine the prognosis of the disease, guide treatment decisions, and monitor the response to treatment. Patients with higher levels of the BCR/ABL fusion gene may have a more aggressive form of leukemia and may require more intensive treatment.

No FAQs available.

Customer Google Rating